Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients

Investigational New Drugs

Volumn 31, Issue 6, 2013, Pages 1580-1586

  Lee, Jeeyun ^a   Lee, Su Jin ^a   Lee, Jongtae ^b   Park, Se Hoon ^a   Park, Joon Oh ^a   Park, Young Suk ^a   Lim, Ho Yeong ^a   Kim, Kyoung Mee ^a   Do, In Gu ^a,c   Jung, Sin Ho ^c   Yim, Dong Seok ^b   Kang, Won Ki ^a  

^a Sungkyunkwan University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Capecitabine; Chemotherapy; Everolimus; Refractory gastric cancer

Indexed keywords

CAPECITABINE; EVEROLIMUS; FLUOROURACIL;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER CONTROL; CANCER PATIENT; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRY SKIN; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERPIGMENTATION; HYPERTRANSAMINASEMIA; INSOMNIA; JAUNDICE; LUNG FIBROSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY GASTRIC CANCER; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; SIROLIMUS; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84888642452     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0022-0     Document Type: Article

References (29)

1. Levi F, Lucchini F, Gonzalez JR, Fernandez E, Negri E, La Vecchia C (2004) Monitoring falls in gastric cancer mortality in Europe. Ann Oncol 15:338-345
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
3. Tanaka M, Ma E, Tanaka H, Ioka A, Nakahara T, Takahashi H (2012) Trends of stomach cancer mortality in Eastern Asia in 1950-2004: comparative study of Japan, Hong Kong and Singapore using age, period and cohort analysis. Int J Cancer 130:930-936
4. Jung KW, Park S, Kong HJ et al (2012) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat 44:11-24
5. Van Cutsem E, Haller D, Ohtsu A (2002) The role of chemotherapy in the current treatment of gastric cancer. Gastric Cancer 5(Suppl 1):17-22
6. Park SJ, Hong YS, Lee JL et al (2012) Genetic polymorphisms of FcgammaRIIa and FcgammaRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer. Oncology 82:83-89
7. Ji SH, Lim do H, Yi SY et al (2009) A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer 9:110
8. Jiang BH, Liu LZ (2008) Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Update 11:63-76
9. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN (2009) The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 35:148-159
10. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335-348
11. Cejka D, Preusser M, Woehrer A et al (2008) Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther 7:1377-1385
12. Doi T, Muro K, Boku N et al (2010) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 28:1904-1910
13. Bu X, Le C, Jia F et al (2008) Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Cancer Biol Ther 7:392-396
14. Lee KH, Hur HS, Im SA et al (2010) RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer Lett 299:22-28
15. Lim T, Lee J, Lee DJ et al (2011) Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother Pharmacol 68:255-262
16. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
17. Jung SH, Kim KM (2004) On the estimation of the binomial probability in multistage clinical trials. Stat Med 23:881-896
18. CaBT J (1983) Confidence intervals for a binomial parameter following a multistage test with application to MIL-STD 105D and medical trials. Technometrics 25:49-58
19. Jung SH, Owzar K, George SL, Lee T (2006) P-value calculation for multistage phase II cancer clinical trials. J Biopharm Stat 16:765-775, discussion 777-783
20. Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918
21. Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347
22. Tabernero J, Rojo F, Calvo E et al (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610
23. Lang SA, Gaumann A, Koehl GE et al (2007) Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120:1803-1810
24. Fuereder T, Jaeger-Lansky A, Hoeflmayer D et al (2010) mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. Cancer Lett 296:249-256
25. Yoon DH, Ryu MH, Park YS et al (2012) Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106:1039-1044
26. Van Cutsem Eea (2012) Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol 30, 2012 (suppl 4; abstr LBA3)
27. O'Donnell A, Faivre S, Burris HA 3rd et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588-1595
28. Okamoto I, Doi T, Ohtsu A et al (2010) Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 40:17-23
29. Deenen MJ, Klumpen HJ, Richel DJ et al (2012) Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Investig New Drugs 30:1557-1565